Congress hands Trump power to slash medical tariffs with minimal oversight

What it does

This bill authorizes the President to negotiate trade agreements with countries that meet certain criteria—including intellectual property protections, rule of law, and commitment to open medical supply trade during emergencies—to reduce tariffs and trade barriers on medical devices, drugs, and related goods. The goal is to diversify U.S. medical supply sources away from over-reliance on China, Mexico, and Malaysia, and to harmonize regulatory standards across trusted partners to speed up cross-border movement of medical products during public health crises.

Why we flagged it

The bill's core mechanism is executive authority to negotiate tariff reductions and regulatory harmonization on medical goods with pre-approved trading partners. While framed as a national security and public health measure, it functions primarily as a trade liberalization tool that benefits pharmaceutical and medical device manufacturers through reduced barriers and IP harmonization.

What the text implies

• The 'trusted trade partner' criteria (IP protection 'similar to US law,' regulatory harmonization, government procurement access) are designed to benefit multinational pharma and device makers, not necessarily to lower consumer prices or prioritize generic drug access.
• Regulatory harmonization and 'reliance' provisions may allow foreign manufacturing standards to replace U.S. FDA oversight, potentially weakening safety or efficacy review for imported drugs and devices.

The full analysis lists 5 implications of this text.

Who stands to gain

multinational pharmaceutical companies; medical device manufacturers; contract manufacturers in allied countries